Roles of BCL-2 and MDR1 expression in the efficacy of paclitaxel-based lung cancer chemoradiation

Anticancer Research

Volumn 31, Issue 4, 2011, Pages 1431-1436

  Maráz, Anikó ^a   Furák, József ^b   Pálföldi, Regina ^a   Eller, József ^a   Szántó, Erika ^a   Kahán, Zsuzsanna ^a   Thurzó, László ^a   Molnár, József ^c   Tiszlavicz, László ^a   Hideghéty, Katalin ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF SZEGED   (Hungary)

Author keywords

BCL 2; Lung cancer; MDR1; Paclitaxel based chemoradiotherapy; Radiosensitivity

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; MULTIDRUG RESISTANCE PROTEIN 1; PACLITAXEL; PROTEIN BCL 2;

ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SIZE; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RADIATION DOSE; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LUNG NEOPLASMS; MALE; MIDDLE AGED; P-GLYCOPROTEIN; PACLITAXEL; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIOTHERAPY DOSAGE; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 79956136147     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Rigas J and Karen K: Current treatment paradigms for locally advanced non-small cell lung cancer. J Thorac Oncol 2: S77-S85, 2007.
2. Choy H, Pyo H, Kim JS and MacRae R: Role of taxanes in the combined modality treatment of patients with locally advanced non-small cell lung cancer. Exp Op Pharmacot 2: 963-974, 2001. (Pubitemid 32754815)
3. Fournel P, Robinet G, Thomas P, Souquet PJ, Léna H, Vergnenégre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daurés JP, Mornex F and Pérol M: Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de PneumoCancérologie NPC 95-01 Study. J Clin Oncol 23: 5910-5917, 2005.
4. Nyman J, Friesland S, Hallqvist A, Seke M, Bergström S, Thaning L, Lödén B, Sederholm C and Wagenius G: How to improve loco-regional control in stages IIIa-b NSCLC. Results of a three-armed randomized trial from the Swedish Lung Cancer Study Group. Lung Cancer 65: 62-67, 2009.
5. Zhang H, Hyrien O, Pandya KJ, Keng PC and Chen Y: Tumor response kinetics after schedule-dependent paclitaxel chemoradiation treatment for inoperable non-small cell lung cancer a model for low-dose chemotherapy radiosensitization. J Thorac Oncol 3: 563-568, 2008. (Pubitemid 351787297)
6. Tishler RB, Schiff PB, Geard CR and Hall EJ: Taxol: a novel radiation sensitizer. Int J Radiat Oncol Biol Phys 22: 613-617, 1992.
7. Moldvay J, Scheid P, Wild P, Nabil K, Siat J, Borrelly J, Marie B, Farré G, Labib T, Pottier G, Sesboüé R, Bronner C, Vignaud JM, Martinet Y and Martinet N: Predictive survival markers in patients with surgically resected non-small cell lung carcinoma. Clin Cancer Res 6: 1125-34, 2000. (Pubitemid 30159376)
8. Anagnostou VK, Lowery FJ, Zolota V, Tzelepi V, Gopinath A, Liceaga C, Panagopoulos N, Frangia K, Tanoue L, Boffa D, Gettinger S, Detterbeck F, Homer RJ, Dougenis D, Rimm DL and Syrigos KN: High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology. BMC Cancer 10: 186, 2010.
9. Martin B, Paesmans M, Berghmans T, Branle F, Ghisdal L, Mascaux C, Meert AP, Steels E, Vallot F, Verdebout JM, Lafitte JJ and Sculier JP: Role of BCL-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 89: 55-64, 2003. (Pubitemid 36897935)
10. Fokkema E, Timens W, de Vries EG, de Jong S, Fidler V, Meijer C and Groen HJ: Expression and prognostic implications of apoptosis-related proteins in locally unresectable non-small cell lung cancers. Lung Cancer 52: 241-247, 2006.
11. Hwang JH, Lim SC, Kim YC, Park KO, Ahn SJ and Chung WK: Apoptosis and BCL-2 expression as predictors of survival in radiation-treated non-small cell lung cancer. Int J Radiat Oncol Biol Phys 50: 13-18, 2001.
12. Groeger AM, Esposito V, De Luca A, Cassandra R, Tonini G, Ambrogi V, Baldi F, Goldfarb R, Mineo TC, Baldi A and Wolner E: Prognostic value of immunohistochemical expression of p53, BAX, BCL-2 and BCL-xL in resected non-small cell lung cancers. Histopathology 44: 54-63, 2004. (Pubitemid 38174871)
13. Poleri C, Morero JL, Nieva B, Vázquez MF, Rodríguez C, de Titto E and Rosenberg M: Risk of recurrence in patients with surgically resected stage I non-small cell lung carcinoma: histopathologic and immunohistochemical analysis. Chest 123: 1858-1867, 2003.
14. Matsumoto H, Wada T, Fukunaga K, Yoshihiro S, Matsuyama H and Naito K: BAX to BCL-2 ratio and Ki-67 index are useful predictors of neoadjuvant chemoradiation therapy in bladder cancer. Jpn J Clin Oncol 34: 124-130, 2004. (Pubitemid 43102903)
15. Font A, Rigas JR, Eastman A, Memolid VA, Colee BF, Hammondf S and Rosell R: Expression of apoptosis-related proteins and response to chemoradiotherapy and prognosis in esophageal cancer. Clin Transi Oncol 2: 146-153, 2000.
16. Kuremsky JG, Tepper JE and McLeod HL: Biomarkers for response to neoadjuvant chemoradiation for rectal cancer. Int J Radiat Oncol Biol Phys 74: 673-88, 2009.
17. Mannarini L, Bertino G, Morbini P, Villa C and Benazzo M: Markers of chemoradiation resistance in patients with locally advanced head and neck squamous cell carcinoma, treated by intra-arterial carboplatin and concurrent radiation. Acta Otorhinolaryngol Ital 27: 173-180, 2007.
18. Jeong SH, Jung JH, Han JH, Kim JH, Choi YW, Lee HW, Kang SY, Hwang YH, Ahn MS, Choi JH, Oh YT, Chun M, Kang S, Park KJ, Hwang SC and Sheen SS: Expression of BCL-2 predicts outcome in locally advanced non-small cell lung cancer patients treated with cisplatin-based concurrent chemoradiotherapy. Lung Cancer 68: 288-294, 2010.
19. Michaud WA, Nichols AC, Mroz EA, Faquin WC, Clark JR, Begum S, Westra WH, Wada H, Busse PM, Ellisen LW and Rocco JW: BCL-2 blocks cisplatin-induced apoptosis and predicts poor outcome following chemoradiation treatment in advanced oropharyngeal squamous cell carcinoma. Clin Cancer Res 15: 1645-1654, 2009.
20. Mini E and Nobili S: Pharmacogenetics: implementing personalized medicine. Clin Cases Miner Bone Metab 6: 17-24, 2009.
21. Zaman GJR, Flens MJ, Van Leusden MR, Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F and Broxterman HJ: The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Med Science 91: 8822-8826, 1994.
22. Ding S, Chamberlain M, McLaren A, Goh L, Duncan I and Wolf CR: Cross-talk between signalling pathways and the multidrug resistant protein MDR-1. Br J Cancer 85: 1175-1184, 2001. (Pubitemid 33052318)
23. Nobili S, Landini I, Giglioni B and Mini E: Pharmacological strategies for overcoming multidrug resistance. Curr Drug Targets 7: 861-879, 2006.
24. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Glabbeke MV, Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92: 205-216, 2000. (Pubitemid 30099779)
25. Srivastava RK, Srivastava AR, Korsmeyer SJ, Nesterova M, Cho-Chung YS and Longo DL: Involvement of microtubules in the regulation of BCL2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. Mol Cell Biol 18: 3509-3517, 1998.
26. Abal M, Andreu JM and Barasoain I: Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3: 193-203, 2003. (Pubitemid 36565761)
27. Ferlini C, Raspaglio G, Mozzetti S, Distefano M, Filippetti F, Martinelli E, Ferrandina G, Gallo D, Ranelletti FO and Scambia G: BCL-2 down-regulation is a novel mechanism of paclitaxel resistance. Mol Pharmacol 64: 51-58, 2003. (Pubitemid 36759817)
28. Lee HW, Choi YW, Han JH, Kim JH, Jung JH, Jeong SH, Kang SY, Choi JH, Oh YT, Park KJ, Hwang SC and Sheen SS: Expression of excision repair crosscomplementation group 1 protein predicts poor outcome in advanced non-small cell lung cancer patients treated with platinum-based doublet chemotherapy. Lung Cancer 65: 377-382, 2009.
29. Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L and Tonato M: Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors. Tumori 94: 398-405, 2008.
30. Wang J, Wang H, Zhao L, Fan S, Yang Z, Gao F, Chen L, Xiao GG, Molnár J and Wang Q: Down-regulation of P-glycoprotein is associated with resistance to cisplatin and VP-16 in human lung cancer cell lines. Anticancer Res 30: 3593-3598, 2010.